Drug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board.
He said: “I am delighted to be joining the board of Storm and working with the company in this exploding area of biology.
“RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies.
“I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”
Workman currently serves The Institute of Cancer Research as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research UK.
Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent director to Storm’s board.
“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed.
“We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”